CELL THERAPY MANUFACTURING MARKET ANALYSIS

Cell Therapy Manufacturing Market, By Therapy Type (Allogeneic Cell Therapy and Autologous Cell Therapy), By Technology Type (Somatic Cell Technology, Cell Immortalization Technology, Viral Vector Technology, Genome Editing Technology, Cell Plasticity Technology, 3D Technology), By Manufacturing Purpose (Clinical, Commercial, Pre-clinical), By Application (Musculoskeletal, Cardiovascular, Gastrointestinal, Neurological, Oncology, Dermatology, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : May 2024
Code : CMI1728
Pages :205
Formats :
Excel and PDF
Industry : Biotechnology

Market Concentration and Competitive Landscape

Cell Therapy Manufacturing Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

Increasing Regulatory Approvals by Regulatory Authorities

Manufacturers of cell therapy product are focusing on receiving regulatory approvals to enhance their cell therapy manufacturing process, and this is expected to drive the global cell therapy manufacturing market growth. For instance, in May 2022, Bristol Myers Squibb Company, a pharmaceutical company, announced that the U.S. Food and Drug Administration had approved Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Key Players Insights